179 related articles for article (PubMed ID: 36291047)
21. Parkinson's disease and multiple system atrophy have distinct α-synuclein seed characteristics.
Yamasaki TR; Holmes BB; Furman JL; Dhavale DD; Su BW; Song ES; Cairns NJ; Kotzbauer PT; Diamond MI
J Biol Chem; 2019 Jan; 294(3):1045-1058. PubMed ID: 30478174
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis.
Eusebi P; Giannandrea D; Biscetti L; Abraha I; Chiasserini D; Orso M; Calabresi P; Parnetti L
BMJ Open; 2016 Jun; 6(6):e011113. PubMed ID: 27297011
[TBL] [Abstract][Full Text] [Related]
23. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
[TBL] [Abstract][Full Text] [Related]
24. A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of α-synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in α-synuclein research.
Kumar ST; Donzelli S; Chiki A; Syed MMK; Lashuel HA
J Neurochem; 2020 Apr; 153(1):103-119. PubMed ID: 31925956
[TBL] [Abstract][Full Text] [Related]
25. Parkinson's and Lewy body dementia CSF biomarkers.
Parnetti L; Paciotti S; Farotti L; Bellomo G; Sepe FN; Eusebi P
Clin Chim Acta; 2019 Aug; 495():318-325. PubMed ID: 31051162
[TBL] [Abstract][Full Text] [Related]
26. A photoelectrochemical immunosensor based on Au-doped TiO2 nanotube arrays for the detection of α-synuclein.
An Y; Tang L; Jiang X; Chen H; Yang M; Jin L; Zhang S; Wang C; Zhang W
Chemistry; 2010 Dec; 16(48):14439-46. PubMed ID: 21038326
[TBL] [Abstract][Full Text] [Related]
27. Nanozyme-based cascade SPR signal amplification for immunosensing of nitrated alpha-synuclein.
Hu X; Hu R; Zhu H; Chen Q; Lu Y; Chen J; Liu Y; Chen H
Mikrochim Acta; 2022 Sep; 189(10):367. PubMed ID: 36056240
[TBL] [Abstract][Full Text] [Related]
28. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
29. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
[TBL] [Abstract][Full Text] [Related]
30. ɑ-Synuclein strains and the variable pathologies of synucleinopathies.
Peelaerts W; Baekelandt V
J Neurochem; 2016 Oct; 139 Suppl 1():256-274. PubMed ID: 26924014
[TBL] [Abstract][Full Text] [Related]
31. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J
Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044
[TBL] [Abstract][Full Text] [Related]
32. A novel, label-free liquid crystal biosensor for Parkinson's disease related alpha-synuclein.
Yang X; Li H; Zhao X; Liao W; Zhang CX; Yang Z
Chem Commun (Camb); 2020 May; 56(40):5441-5444. PubMed ID: 32292959
[TBL] [Abstract][Full Text] [Related]
33. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
[TBL] [Abstract][Full Text] [Related]
34. Antibodies against alpha-synuclein: tools and therapies.
Vaikath NN; Hmila I; Gupta V; Erskine D; Ingelsson M; El-Agnaf OMA
J Neurochem; 2019 Sep; 150(5):612-625. PubMed ID: 31055836
[TBL] [Abstract][Full Text] [Related]
35. Methods for detecting toxic α-synuclein species as a biomarker for Parkinson's disease.
O'Hara DM; Kalia SK; Kalia LV
Crit Rev Clin Lab Sci; 2020 Aug; 57(5):291-307. PubMed ID: 32116096
[TBL] [Abstract][Full Text] [Related]
36. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases.
Sengupta U; Kayed R
Prog Neurobiol; 2022 Jul; 214():102270. PubMed ID: 35447272
[TBL] [Abstract][Full Text] [Related]
37. Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study.
Iranzo A; Fairfoul G; Ayudhaya ACN; Serradell M; Gelpi E; Vilaseca I; Sanchez-Valle R; Gaig C; Santamaria J; Tolosa E; Riha RL; Green AJE
Lancet Neurol; 2021 Mar; 20(3):203-212. PubMed ID: 33609478
[TBL] [Abstract][Full Text] [Related]
38. An α-helical peptide-based plasmonic biosensor for highly specific detection of α-synuclein toxic oligomers.
Giarola JF; Santos J; Estevez MC; Ventura S; Pallarès I; Lechuga LM
Anal Chim Acta; 2024 May; 1304():342559. PubMed ID: 38637056
[TBL] [Abstract][Full Text] [Related]
39. Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder.
Stefani A; Iranzo A; Holzknecht E; Perra D; Bongianni M; Gaig C; Heim B; Serradell M; Sacchetto L; Garrido A; Capaldi S; Sánchez-Gómez A; Cecchini MP; Mariotto S; Ferrari S; Fiorini M; Schmutzhard J; Cocchiara P; Vilaseca I; Brozzetti L; Monaco S; Jose Marti M; Seppi K; Tolosa E; Santamaria J; Högl B; Poewe W; Zanusso G;
Brain; 2021 May; 144(4):1118-1126. PubMed ID: 33855335
[TBL] [Abstract][Full Text] [Related]
40. [Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies].
Orimo S
Rinsho Shinkeigaku; 2008 Jan; 48(1):11-24. PubMed ID: 18386627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
